Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:51 UTC |
---|
Update Date | 2022-03-07 02:51:49 UTC |
---|
HMDB ID | HMDB0015007 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Dorzolamide |
---|
Description | Dorzolamide is only found in individuals that have used or taken this drug. It is a carbonic anhydrase (CA) inhibitor. It is used in ophthalmic solutions (Trusopt) to lower intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension.Dorzolamide is a sulfonamide and a highly specific carbonic anhydrase II (CA-II) inhibitor, which is the main CA isoenzyme involved in aqueous humor secretion. Inhibition of CA-II in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Dorzolamide also accumulates in red blood cells as a result of CA-II binding, as CA-II is found predominantly in erythrocytes. However, sufficient CA-II activity remains so that adverse effects due to systemic CA inhibition are not observed. |
---|
Structure | CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O InChI=1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)/t6-,8-/m0/s1 |
---|
Synonyms | Value | Source |
---|
(4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide | ChEBI | (4S,trans)-4-(Ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide | ChEBI | (4S-trans)-4-(ETHYLAMINO)-5,6-dihydro-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide | ChEBI | 4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide | ChEBI | 4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonic acid amide | ChEBI | 4S,6S-Dorzolamide | ChEBI | Trusopt | Kegg | (4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonate amide | Generator | (4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulphonate amide | Generator | (4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulphonic acid amide | Generator | (4S,trans)-4-(Ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulphonamide 7,7-dioxide | Generator | (4S-trans)-4-(ETHYLAMINO)-5,6-dihydro-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulphonamide-7,7-dioxide | Generator | 4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonate amide | Generator | 4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulphonate amide | Generator | 4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulphonic acid amide | Generator | 4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonate amide | Generator | 4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulphonate amide | Generator | 4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulphonic acid amide | Generator | 5,6-Dihydro-4-ethylamino-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide | HMDB | Dorzolamide hydrochloride | HMDB | Dorzolamide chibret | HMDB | Dorzolamide, (trans)-isomer | HMDB | 4-Ethylamino-5,6-dihydro-6-methyl-7,7-dioxide-4H-thieno(2,3-b)thiopyran-2-sulfonamide | HMDB |
| Show more...
---|
Chemical Formula | C10H16N2O4S3 |
---|
Average Molecular Weight | 324.44 |
---|
Monoisotopic Molecular Weight | 324.02721908 |
---|
IUPAC Name | (2S,4S)-4-(ethylamino)-2-methyl-1,1-dioxo-2H,3H,4H-1λ⁶-thieno[2,3-b]thiopyran-6-sulfonamide |
---|
Traditional Name | dorzolamide |
---|
CAS Registry Number | 120279-96-1 |
---|
SMILES | CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O |
---|
InChI Identifier | InChI=1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)/t6-,8-/m0/s1 |
---|
InChI Key | IAVUPMFITXYVAF-XPUUQOCRSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as 2,3,5-trisubstituted thiophenes. These are organic compounds containing a thiophene that is trisubstituted at the C-2, C3- and C5-positions. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Thiophenes |
---|
Sub Class | 2,3,5-trisubstituted thiophenes |
---|
Direct Parent | 2,3,5-trisubstituted thiophenes |
---|
Alternative Parents | |
---|
Substituents | - 2,3,5-trisubstituted thiophene
- Aralkylamine
- Organosulfonic acid amide
- Thiopyran
- Sulfone
- Organic sulfonic acid or derivatives
- Organosulfonic acid or derivatives
- Sulfonyl
- Aminosulfonyl compound
- Heteroaromatic compound
- Secondary aliphatic amine
- Secondary amine
- Organonitrogen compound
- Organic nitrogen compound
- Amine
- Organic oxygen compound
- Organosulfur compound
- Organopnictogen compound
- Organic oxide
- Hydrocarbon derivative
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 283 - 285 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.7 g/L | Not Available | LogP | -1 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | | Show more...
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Dorzolamide,1TMS,isomer #1 | CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N[Si](C)(C)C)S2 | 2800.1 | Semi standard non polar | 33892256 | Dorzolamide,1TMS,isomer #1 | CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N[Si](C)(C)C)S2 | 2788.2 | Standard non polar | 33892256 | Dorzolamide,1TMS,isomer #1 | CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N[Si](C)(C)C)S2 | 3771.2 | Standard polar | 33892256 | Dorzolamide,1TMS,isomer #2 | CCN([C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2)[Si](C)(C)C | 2839.5 | Semi standard non polar | 33892256 | Dorzolamide,1TMS,isomer #2 | CCN([C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2)[Si](C)(C)C | 2882.7 | Standard non polar | 33892256 | Dorzolamide,1TMS,isomer #2 | CCN([C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2)[Si](C)(C)C | 4592.2 | Standard polar | 33892256 | Dorzolamide,2TMS,isomer #1 | CCN([C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N[Si](C)(C)C)S2)[Si](C)(C)C | 2802.5 | Semi standard non polar | 33892256 | Dorzolamide,2TMS,isomer #1 | CCN([C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N[Si](C)(C)C)S2)[Si](C)(C)C | 3011.7 | Standard non polar | 33892256 | Dorzolamide,2TMS,isomer #1 | CCN([C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N[Si](C)(C)C)S2)[Si](C)(C)C | 3650.3 | Standard polar | 33892256 | Dorzolamide,2TMS,isomer #2 | CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N([Si](C)(C)C)[Si](C)(C)C)S2 | 2819.1 | Semi standard non polar | 33892256 | Dorzolamide,2TMS,isomer #2 | CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N([Si](C)(C)C)[Si](C)(C)C)S2 | 2982.7 | Standard non polar | 33892256 | Dorzolamide,2TMS,isomer #2 | CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N([Si](C)(C)C)[Si](C)(C)C)S2 | 3670.7 | Standard polar | 33892256 | Dorzolamide,3TMS,isomer #1 | CCN([C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N([Si](C)(C)C)[Si](C)(C)C)S2)[Si](C)(C)C | 2860.2 | Semi standard non polar | 33892256 | Dorzolamide,3TMS,isomer #1 | CCN([C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N([Si](C)(C)C)[Si](C)(C)C)S2)[Si](C)(C)C | 3209.7 | Standard non polar | 33892256 | Dorzolamide,3TMS,isomer #1 | CCN([C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N([Si](C)(C)C)[Si](C)(C)C)S2)[Si](C)(C)C | 3543.7 | Standard polar | 33892256 | Dorzolamide,1TBDMS,isomer #1 | CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N[Si](C)(C)C(C)(C)C)S2 | 3032.7 | Semi standard non polar | 33892256 | Dorzolamide,1TBDMS,isomer #1 | CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N[Si](C)(C)C(C)(C)C)S2 | 3049.4 | Standard non polar | 33892256 | Dorzolamide,1TBDMS,isomer #1 | CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N[Si](C)(C)C(C)(C)C)S2 | 3819.2 | Standard polar | 33892256 | Dorzolamide,1TBDMS,isomer #2 | CCN([C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2)[Si](C)(C)C(C)(C)C | 3064.2 | Semi standard non polar | 33892256 | Dorzolamide,1TBDMS,isomer #2 | CCN([C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2)[Si](C)(C)C(C)(C)C | 3126.0 | Standard non polar | 33892256 | Dorzolamide,1TBDMS,isomer #2 | CCN([C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2)[Si](C)(C)C(C)(C)C | 4640.5 | Standard polar | 33892256 | Dorzolamide,2TBDMS,isomer #1 | CCN([C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N[Si](C)(C)C(C)(C)C)S2)[Si](C)(C)C(C)(C)C | 3218.1 | Semi standard non polar | 33892256 | Dorzolamide,2TBDMS,isomer #1 | CCN([C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N[Si](C)(C)C(C)(C)C)S2)[Si](C)(C)C(C)(C)C | 3529.1 | Standard non polar | 33892256 | Dorzolamide,2TBDMS,isomer #1 | CCN([C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N[Si](C)(C)C(C)(C)C)S2)[Si](C)(C)C(C)(C)C | 3708.8 | Standard polar | 33892256 | Dorzolamide,2TBDMS,isomer #2 | CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)S2 | 3272.6 | Semi standard non polar | 33892256 | Dorzolamide,2TBDMS,isomer #2 | CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)S2 | 3496.4 | Standard non polar | 33892256 | Dorzolamide,2TBDMS,isomer #2 | CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)S2 | 3711.3 | Standard polar | 33892256 | Dorzolamide,3TBDMS,isomer #1 | CCN([C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)S2)[Si](C)(C)C(C)(C)C | 3456.7 | Semi standard non polar | 33892256 | Dorzolamide,3TBDMS,isomer #1 | CCN([C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)S2)[Si](C)(C)C(C)(C)C | 3981.5 | Standard non polar | 33892256 | Dorzolamide,3TBDMS,isomer #1 | CCN([C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(=O)(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)S2)[Si](C)(C)C(C)(C)C | 3656.8 | Standard polar | 33892256 |
| Show more...
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Dorzolamide GC-MS (Non-derivatized) - 70eV, Positive | splash10-0ar3-2393000000-5fee748c257c96fe4cc6 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Dorzolamide GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Dorzolamide GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dorzolamide 10V, Positive-QTOF | splash10-004i-1039000000-bc26f50a987e66b2d85f | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dorzolamide 20V, Positive-QTOF | splash10-0udi-1940000000-b593686cdeed391e6252 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dorzolamide 40V, Positive-QTOF | splash10-0006-9200000000-37bcca2a8a93f29e705e | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dorzolamide 10V, Negative-QTOF | splash10-00b9-7495000000-d579bf9a53d7355310be | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dorzolamide 20V, Negative-QTOF | splash10-0fa9-5960000000-4180bf8ab95c96f57f15 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dorzolamide 40V, Negative-QTOF | splash10-004i-9010000000-0ef2ea7db65e541aecef | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dorzolamide 10V, Positive-QTOF | splash10-004i-0009000000-2467b7c2962f7a83efdc | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dorzolamide 20V, Positive-QTOF | splash10-004i-0097000000-a04c8c4869eb06d72260 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dorzolamide 40V, Positive-QTOF | splash10-016r-0390000000-5e9ea339d753845f7c98 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dorzolamide 10V, Negative-QTOF | splash10-00di-0009000000-77ced8018945af0b8737 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dorzolamide 20V, Negative-QTOF | splash10-00dr-4439000000-3349264d7067d02efbca | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Dorzolamide 40V, Negative-QTOF | splash10-004i-9740000000-a0afe72c11e381401a2f | 2021-10-11 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum |
| Show more...
---|
Biological Properties |
---|
Cellular Locations | |
---|
Biospecimen Locations | |
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00869 | | details | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00869 | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB00869 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 4447604 |
---|
KEGG Compound ID | C06969 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Dorzolamide |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 5284549 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 4702 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Balfour JA, Wilde MI: Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging. 1997 May;10(5):384-403. [PubMed:9143858 ]
- Ponticello GS, Sugrue MF, Plazonnet B, Durand-Cavagna G: Dorzolamide, a 40-year wait. From an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucoma. Pharm Biotechnol. 1998;11:555-74. [PubMed:9760696 ]
- Martens-Lobenhoffer J, Banditt P: Clinical pharmacokinetics of dorzolamide. Clin Pharmacokinet. 2002;41(3):197-205. [PubMed:11929320 ]
- Almeida GC Jr, Faria e Souza SJ: Effect of topical dorzolamide on rabbit central corneal thickness. Braz J Med Biol Res. 2006 Feb;39(2):277-81. Epub 2006 Feb 2. [PubMed:16470316 ]
- Grover S, Apushkin MA, Fishman GA: Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol. 2006 May;141(5):850-8. Epub 2006 Mar 20. [PubMed:16546110 ]
- Plummer CE, MacKay EO, Gelatt KN: Comparison of the effects of topical administration of a fixed combination of dorzolamide-timolol to monotherapy with timolol or dorzolamide on IOP, pupil size, and heart rate in glaucomatous dogs. Vet Ophthalmol. 2006 Jul-Aug;9(4):245-9. [PubMed:16771760 ]
|
---|